Systemic sclerosis – review of current data and latest reports
DOI:
https://doi.org/10.12775/JEHS.2023.20.01.018Keywords
systemic sclerosis, pathophysiology, treatment, rheumatology, sclerodermaAbstract
Introduction: Systemic scleroderma (SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs, vasculopathy and dysregulation of the immune system. It has the highest mortality rate among rheumatologic diseases. SSc causes high economic and social costs.
Aim of the study: The purpose of this review is to present the current state of knowledge and recent reports on the pathophysiology, clinical manifestation and treatment of SSc.
Materials and methods: A search was conducted using PubMed and GoogleScholar databases. Articles were searched in English using the following keywords: "systemic sclerosis", "scleroderma", "treatment", "symptoms", "pathophysiology".
Conclusions: Although the prognosis of SSc remains poor, optimized patient diagnosis along with ongoing advances in therapy could significantly impact the effectiveness of disease management in the near future. It is anticipated that there will be a growing need for further development of combination therapies to better treat this complex disease.
References
Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007; 66: 940–44.
Elhai M, Meune C, Boubaya M, et al. Mapping and predicting mortality from systemic sclerosis. Ann Rheum Dis 2017; 76: 1897–905.
Watad A, Rosenberg V, Tiosano S, et al. Silicone breast implants and the risk of autoimmune/rheumatic disorders: a real-world analysis. Int J Epidemiol. 2018;47:1846–1854.
Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989–2003.
Thoreau B, Chaigne B, Renaud A, Mouthon L. Treatment of systemic sclerosis. Presse Med. 2021 Apr;50(1):104088. doi: 10.1016/j.lpm.2021.104088. Epub 2021 Oct 28. PMID: 34718109.
Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol. 2010;6:578–587.
Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol. 2012;8:42–54.
Rosendahl, A-H, Schönborn, K, Krieg, T. Pathophysiology of systemic sclerosis (scleroderma). Kaohsiung J Med Sci. 2022; 38: 187–195. https://doi.org/10.1002/kjm2.12505
Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths ID. A study of the prevalence of systemic sclerosis in northeast England. Rheumatology. 2004 Jan 27;43(5):596–602. https://doi. Org/10.1093/rheumatology/keh124
Hughes M, Hodgson R, Harris J et al. Imaging calcinosis in patients with systemic sclerosis by radiography, computerised tomography and magnetic resonance imaging. Semin Arthritis Rheum. 2019 Mar;S0049-0172(18)30705-4. https://doi.org/10.1016/j. Semarthrit.2019.03.001
Racine M, Hudson M, Baron M, Nielson WR, and the Canadian Scleroderma Research Group. The impact of pain and itch on functioning and health-related quality of life in systemic sclerosis: an exploratory study. J Pain Symptom Manage 2016; 52: 43–53.
Razykov I, Levis B, Hudson M, Baron M, Thombs BD, and the Canadian Scleroderma Research Group. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients. Rheumatology 2013; 52: 2056–61.
Shand L, Lunt M, Nihtyanova S, et al. Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 2007; 56: 2422–31.
Khanna D, Nagaraja V, Tseng CH, et al. Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials. Arthritis Res Ther 2015; 17: 372
Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group. Arthritis Rheum 2011; 63: 3078–85.
Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248–54.
Goh NS, Desai SR, Anagnostopoulos C, et al. Increased epithelial permeability in pulmonary fibrosis in relation to disease progression. Eur Respir J 2011; 38: 184–90.
Tashkin DP, Elashoff R, Clements PJ, et al, and the Scleroderma Lung Study Research Group. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med 2007; 176: 1026–34.
Tashkin DP, Roth MD, Clements PJ, et al, and the Sclerodema Lung Study II Investigators. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4: 708–19.
Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66: 1625–35.
Shreiner A, Murray C, Denton C, Khanna D. Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord 2016; 1: 247–56.
Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. Q JM 2007; 100: 485–94.
Guillevin L, Bérezné A, Seror R, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology 2012; 51: 460–67
Allanore Y, Meune C, Vonk MC, et al. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010;69:218–21.
Coghlan G. Does left heart disease cause most systemic sclerosis associated pulmonary hypertension? Eur Respir J 2013;42:888–90.
Pieroni M, De Santis M, Zizzo G, et al. Recognizing and treating myocarditis in recent-onset systemic sclerosis heart disease: potential utility of immunosuppressive therapy in cardiac damage progression. Semin Arthritis Rheum 2014;43:526–35.
Dinser R, Frerix M, Meier FMP, et al. Endocardial and myocardial involvement in systemic sclerosis – is there a relevant inflammatory component? Joint Bone Spine Rev Rhum 2013;80:320–3.
Hughes, M., & Herrick, A. L. (2019). Systemic sclerosis. British Journal of Hospital Medicine, 80(9), 530–536. doi:10.12968/hmed.2019.80.9.530
Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Lancet. 2023 Jan 28;401(10373):304-318. doi: 10.1016/S0140-6736(22)01692-0. Epub 2022 Nov 25. PMID: 36442487; PMCID: PMC9892343.
Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85–118.
Goldin JG, Kim GHJ, Tseng CH, et al. Longitudinal changes in quantitative interstitial lung disease on computed tomography after immunosuppression in the scleroderma lung study II. Ann Am Thorac Soc 2018; 15: 1286–95.
Volkmann ER, Tashkin DP, LeClair H, et al. Treatment with mycophenolate and cyclophosphamide leads to clinically meaningful improvements in patient-reported outcomes in scleroderma lung disease: results of scleroderma lung study II. ACR Open Rheumatol 2020; 2: 362–70.
Namas R, Tashkin DP, Furst DE, et al. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res 2018; 70: 439–44.
Ahlmann M, Hempel G. The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. Cancer Chemother Pharmacol 2016; 78: 661–71.
Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655–66.
Faurschou M, Mellemkjaer L, Voss A, Keller KK, Hansen IT, Baslund B. Prolonged risk of specific malignancies following cyclophosphamide therapy among patients with granulomatosis with polyangiitis. Rheumatology 2015; 54: 1345–50.
Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47: 115–23.
Maher TM, Tudor V, Saunders P, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease associated interstitial lung disease (RECITAL): a multi-centre randomized controlled trial. San Fransisco: ATS, 2022.
Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol 2021; 3: e489–97.
Goswami RP, Ray A, Chatterjee M, Mukherjee A, Sircar G, Ghosh P. Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis. Rheumatology 2021; 60: 557–67.
van Laar JM, Farge D, Sont JK, et al. Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 2014; 311: 2490–8.
Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015; 45: 1434–45.
Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019; 380: 2518–28.
Roofeh D, Lin CJF, Goldin J, et al. Tocilizumab prevents progression of early systemic sclerosis-associated interstitial lung disease. Arthritis Rheumatol 2021; 73: 1301–10.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Radosław Kasperski, Tomasz Łoś, Anna Sobstyl, Dominik Dudziński, Małgorzata Piekarska-Kasperska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 320
Number of citations: 0
